Why Use Fluconazole Treatment

One of the nastiest types of infection is fungal infection.  Although they are more likely to grow on the skin, there are more serious ones though that develops in the respiratory system and infect not just the lungs, but also the blood and other parts of the body’s internal structure.  When you develop a fungal infection, it is vital that you treat the infection as soon as possible to prevent further growth, development, and spread of the infection.  Failure to do so may mean longer and costlier treatment.  Fluconazole treatment is needed for treating fungal infection.  Fluconazole treatment is an antifungal medication treatment that you take orally.

Most antifungals are applied on the skin directly to where the infection has developed.  However, if the infection has buried further or deeper in to the skin, or the infection has developed inside of the body, such topical type of antifungal will not work on such.  For cases like this, fluconazole treatment is necessary as fluconazole treatment comes in pill form which you take orally.  The treatment process in using fluconazole treatment is the purging of the infection from the inside of your body.  This effectively gets rid of the infection from your system.

For antifungal fluconazole treatment, it is necessary that you use fluconazole treatment for a course of several days.  The number of days you need to use fluconazole treatment depends on the type of infection that you have developed and the severity that it has.  Course treatment is necessary in completely getting rid of an infection from the body.  This is the very reason why doctors prescribe patients with several days of use of fluconazole treatment when they have a fungal infection.  By completing the course of fluconazole treatment, you will be able to completely purge the fungal infection out of the body. Read more…

MS and the powers that be


At least 55,000 Canadians have multiple sclerosis, 3,500 of whom live in Saskatchewan. No one’s sure why our country is home to so many MS sufferers. Brad Wall, Premier of Saskatchewan, has taken a bold move in promising to help finance clinical trials on an unproven but promising new treatment – the “liberation procedure.” He’d like other premiers to follow suit. However, Ontario Premier Dalton McGuinty isn’t convinced the controversial treatment is ready for testing. So, afflicted Canadians are traveling to Bulgaria, Poland, Costa Rica, Italy and India, where the procedure is available, to benefit -- even if only minimally – from any relief it may offer, at an average of $30,000 a pop.

MS patients may have a range of symptoms that include balance problems, vision impairment, muscle spasms and weakness, diplopia, dysphagia, extreme fatigue, chronic or acute pain, and bladder and bowel difficulties, including incontinence. And the majority tends to live about as long as the healthy population.

It seems only natural that a minimally invasive procedure would be worth the risk to such individuals.

Dr. Paolo Zamboni, an Italian neurologist and director of vascular diseases, came up with the liberation therapy theory at the University of Ferrara, while trying to help his wife, who has the disease ). Examination of the venous system of MS patients showed that 90% had stenosis or restricted valves in the jugular and azygos veins, interfering with blood draining. He also found high levels of iron deposits in their brains, which he surmised might be the cause of the abnormal MS immune response, where the immune system attacks the myelin sheath of brain and spinal cord nerves, causing scarring and plaques.

Dr. Zamboni dubbed the phenomenon “chronic cerebrospinal venous insufficiency” and used a type of angioplasty to relieve the blockage in these veins. He found 73% of his patients improved. But after about nine months, “re-stenosis” made it necessary to repeat the procedure.

Despite this drawback, it seems clear, with so many positive anecdotal reports on the Internet, that Canadian governments should consider giving more attention to this possible break-through therapy. Either that, or launching a thorough investigation of Canadian Hutterites, a group known to have a much lower than average risk of contracting MS.